Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02320227 · ClinicalTrials.gov registry record · NA
A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects
A NA study, sponsored by Church & Dwight Company.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02320227: Completed NA study, sponsored by Church & Dwight Company.
NCT02320227 is a NA study that has completed, run by Church & Dwight Company. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02320227, a NA study, has completed, sponsored by Church & Dwight Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
To evaluate the safety of a personal lubricant when used as indicated as a personal lubricant in the vagina and vulvar/perineal areas at least four times weekly for two weeks in a population of healthy females
Primary Outcome
Number of participants with observed local erythema by OB/GYN examination.
Interventions
- DEVICE Miami w/o frag Personal lubricant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-01 |
| Phase | NA |
What the finished NCT02320227 record still lists
NCT02320227 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Miami w/o frag Personal lubricant is the first listed.
NCT02320227 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02320227 about?
NCT02320227 is a clinical study titled "A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects". To evaluate the safety of a personal lubricant when used as indicated as a personal lubricant in the vagina and vulvar/perineal areas at least four times weekly for two weeks in a population of healthy females
What is the current status of trial NCT02320227?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2014-12. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02320227?
The interventions under investigation include: Miami w/o frag Personal lubricant (DEVICE).
Who is sponsoring clinical trial NCT02320227?
This trial is sponsored by Church & Dwight Company, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02320227's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia